NasdaqCM - Delayed Quote USD

NeoGenomics, Inc. (NEO)

14.16 +0.74 (+5.51%)
At close: April 23 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Christopher Michael Smith BSc CEO & Director 2.86M -- 1963
Mr. Jeffrey S. Sherman M.B.A. Chief Financial Officer 1.17M -- 1966
Mr. Vishal Sikri President of Advanced Diagnostics 1.08M -- 1976
Ms. Melody Harris Esq., J.D. President & COO of Informatics 1.4M -- 1967
Mr. Warren Stone Chief Commercial Officer 1.42M -- 1973
Ms. Kendra Sweeney Vice President of Investor Relations & Communications -- -- --
Ms. Alicia Olivo Executive VP of Business Development, General Counsel & Corporate Secretary -- -- 1984
Mr. Hutan Hashemi J.D. Chief Compliance Officer -- -- 1979
Dr. Derek Lyle M.D. Chief Medical Officer -- -- --
Mr. Gary Passman Chief Culture Officer -- -- --

NeoGenomics, Inc.

9490 NeoGenomics Way
Fort Myers, FL 33912
United States
239 768 0600 https://www.neogenomics.com
Sector: 
Healthcare
Full Time Employees: 
2,100

Description

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Corporate Governance

NeoGenomics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 4; Board: 2; Shareholder Rights: 3; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Apr 30, 2024
NeoGenomics, Inc. Earnings Call

Related Tickers

NTRA Natera, Inc.
91.04
+2.74%
 
MYGN Myriad Genetics, Inc.
18.60
+0.59%
 
VCYT Veracyte, Inc.
19.83
-0.10%
 
GH Guardant Health, Inc.
17.34
-1.42%
 
NEOG Neogen Corporation
12.31
+4.50%
 
CDNA CareDx, Inc
8.23
+0.73%
 
PSNL Personalis, Inc.
1.3800
+9.52%
 
EXAS Exact Sciences Corporation
63.53
+1.79%
 
SHC Sotera Health Company
11.38
+2.61%
 
NOTV Inotiv, Inc.
4.8500
+9.73%